158 related articles for article (PubMed ID: 14732707)
1. Similarity of binding sites of human matrix metalloproteinases.
Lukacova V; Zhang Y; Mackov M; Baricic P; Raha S; Calvo JA; Balaz S
J Biol Chem; 2004 Apr; 279(14):14194-200. PubMed ID: 14732707
[TBL] [Abstract][Full Text] [Related]
2. Specificity of binding with matrix metalloproteinases.
Gupta SP; Patil VM
Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
[TBL] [Abstract][Full Text] [Related]
4. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
[TBL] [Abstract][Full Text] [Related]
5. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses.
Eckhard U; Huesgen PF; Schilling O; Bellac CL; Butler GS; Cox JH; Dufour A; Goebeler V; Kappelhoff R; Keller UAD; Klein T; Lange PF; Marino G; Morrison CJ; Prudova A; Rodriguez D; Starr AE; Wang Y; Overall CM
Matrix Biol; 2016 Jan; 49():37-60. PubMed ID: 26407638
[TBL] [Abstract][Full Text] [Related]
6. Dissecting MMP P
Tokmina-Roszyk M; Fields GB
J Biol Chem; 2018 Oct; 293(43):16661-16676. PubMed ID: 30185620
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
Bode W; Maskos K
Biol Chem; 2003 Jun; 384(6):863-72. PubMed ID: 12887053
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B; Matter H
J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
[TBL] [Abstract][Full Text] [Related]
9. Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases.
Geng L; Gao J; Cui W; Tang Y; Ji M; Chen B
J Comput Aided Mol Des; 2012 Dec; 26(12):1327-42. PubMed ID: 23224743
[TBL] [Abstract][Full Text] [Related]
10. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
Terp GE; Cruciani G; Christensen IT; Jørgensen FS
J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
[TBL] [Abstract][Full Text] [Related]
11. Analysis of X-ray structures of matrix metalloproteinases via chaotic map clustering.
Giangreco I; Nicolotti O; Carotti A; De Carlo F; Gargano G; Bellotti R
BMC Bioinformatics; 2010 Oct; 11():500. PubMed ID: 20932281
[TBL] [Abstract][Full Text] [Related]
12. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
Maskos K; Bode W
Mol Biotechnol; 2003 Nov; 25(3):241-66. PubMed ID: 14668538
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases: fold and function of their catalytic domains.
Tallant C; Marrero A; Gomis-Rüth FX
Biochim Biophys Acta; 2010 Jan; 1803(1):20-8. PubMed ID: 19374923
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
16. A comparative docking study and the design of potentially selective MMP inhibitors.
Hanessian S; Moitessier N; Therrien E
J Comput Aided Mol Des; 2001 Oct; 15(10):873-81. PubMed ID: 11918074
[TBL] [Abstract][Full Text] [Related]
17. Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF
Erdeljac N; Thiehoff C; Jumde RP; Daniliuc CG; Höppner S; Faust A; Hirsch AKH; Gilmour R
J Med Chem; 2020 Jun; 63(11):6225-6237. PubMed ID: 32379447
[TBL] [Abstract][Full Text] [Related]
18. Collagenolytic Matrix Metalloproteinase Activities toward Peptomeric Triple-Helical Substrates.
Stawikowski MJ; Stawikowska R; Fields GB
Biochemistry; 2015 May; 54(19):3110-21. PubMed ID: 25897652
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors.
Maskos K
Biochimie; 2005; 87(3-4):249-63. PubMed ID: 15781312
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic comparison of structures and homology-models of matrix metalloproteinases.
Andreini C; Banci L; Bertini I; Luchinat C; Rosato A
J Proteome Res; 2004; 3(1):21-31. PubMed ID: 14998159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
